A vaccine against Rabies for both Prophylactic and Post Exposure use. Each dose contains Rabies strain Pasteur RIV inducing more than 2 I.U. in the mouse potency test. The virus is grown on the BHK-21 clone CT cell line inactivated with ß -propiolactone and adsorbed on aluminum phosphate.
Nobivac is a brand under MSD group Animal Health (known as Merck Animal Health in USA and Canada). This company operates in more than 100 countries around the world and pioneer in manufacturing and R&D in Companion animal vaccines. They manufactured the first vaccine in 1985 against Canine Parvovirus by the name NOBIVAC PARVO: The first high titer, low passage vaccine against Canine Parvovirus (CPV) and the first to break through levels of maternally derived antibodies to allow puppies to complete their primary course vaccinations at 12 weeks of age.
Product safety and Hazard:
The product is safe and classified as Non-hazardous as it does not trigger a minimum degree of hazard.
- Swelling at the side of administration.
- Mild fever
Highly effective and trustworthy vaccine. 1ml s/c in all age and breeds.
A number of doses: one dose if administered after 3 month age. If the first dose is administered before 3 month age then administer another dose after 3 month age .
Route of administration: subcutaneously, which is the very convenient route of administration.
Duration of Immunity & Revaccination:
For 3 years. Revaccinate yearly in endemic states.
Occasionally a mild anaphylactic – type hypersensitivity reaction may occur after vaccination. This type of reaction can occur after the injection of any foreign protein and is, in most cases, self – limiting.